Rock Creek Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:RCPIQ)

$0.0010 0.00 (0.00 %)
(As of 12/12/2017 05:09 AM ET)
Previous Close$0.00
Today's Range$0.00 - $0.00
52-Week RangeN/A
Volume76,076 shs
Average Volume56,170 shs
Market Capitalization$200,000.00
P/E RatioN/A
Dividend YieldN/A

About Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ)

Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. The Company's activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine. The Company has completed Phase I safety studies of its product candidate in Europe. In pre-clinical testing, anatabine demonstrates anti-inflammatory activity in a range of in vitro and in vivo assays.

Receive RCPIQ News and Ratings via Email

Sign-up to receive the latest news and ratings for RCPIQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.95) per share
Price / Book0.00


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares170,450,000

Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Frequently Asked Questions

What is Rock Creek Pharmaceuticals' stock symbol?

Rock Creek Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RCPIQ."

How were Rock Creek Pharmaceuticals' earnings last quarter?

Rock Creek Pharmaceuticals Inc (OTCMKTS:RCPIQ) released its quarterly earnings data on Monday, November, 11th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $2.26 million for the quarter, compared to analysts' expectations of $1.70 million. View Rock Creek Pharmaceuticals' Earnings History.

Who are some of Rock Creek Pharmaceuticals' key competitors?

Who are Rock Creek Pharmaceuticals' key executives?

Rock Creek Pharmaceuticals' management team includes the folowing people:

  • Michael John Mullan Ph.D. M.D., Chairman of the Board, Office of President, Chief Executive Officer (Age 59)
  • William L. McMahon, Chief Financial Officer (Age 64)
  • Theodore Jenkins, Secretary, Vice President - Corporate Strategy & Development
  • Lee M. Canaan, Independent Director (Age 59)
  • Robert W. Scannell, Independent Director (Age 57)

How do I buy Rock Creek Pharmaceuticals stock?

Shares of Rock Creek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rock Creek Pharmaceuticals' stock price today?

One share of Rock Creek Pharmaceuticals stock can currently be purchased for approximately $0.00.

How big of a company is Rock Creek Pharmaceuticals?

Rock Creek Pharmaceuticals has a market capitalization of $200,000.00.

How can I contact Rock Creek Pharmaceuticals?

Rock Creek Pharmaceuticals' mailing address is 2040 WHITFIELD AVE. SUITE 300, SARASOTA FL, 34243. The company can be reached via phone at 844-727-0727 or via email at [email protected]

MarketBeat Community Rating for Rock Creek Pharmaceuticals (RCPIQ)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  20 (Vote Underperform)
Total Votes:  41
MarketBeat's community ratings are surveys of what our community members think about Rock Creek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Earnings History and Estimates Chart

Earnings by Quarter for Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ)

Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2013Q3($0.02)$1.70 million$2.26 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ)

No dividend announcements for this company have been tracked by

Insider Trades

Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.89%
Insider Trades by Quarter for Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ)

Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/30/2016Robert ScannellDirectorBuy285,714$0.35$99,999.90View SEC Filing  
(Data available from 1/1/2013 forward)


Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) News Headlines

No headlines for this company have been tracked by

SEC Filings

Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) SEC Filings

DateFilerForm TypeView

Social Media


Financials are not available for this stock.


Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.